Lion TCR
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lion TCR - overview
Established
2016
Location
Singapore, -, Singapore
Primary Industry
Biotechnology
About
Founded in 2016 and based in Singapore, Lion TCR Pte. Ltd. , trading as Lion TCR, is a biotechnology company dedicated to the development and commercialization of our TCR-T therapy. In November 2022, it announces a Poster Presentation of the Phase 1 Study for LioCyx-M at AASLD The Liver Meeting.
Xiaoming Peng is the CEO of the company, graduated from the National University of Singapore, and has over 18 years of working experience at A*STAR. In January 2026, Lion TCR raised a series B+ funding from Wanlian Tianze and Wanlian Securities. Lion TCR uses TCR-T cells for clinical trials against liver cancer to evaluate the safety and effectiveness of TCR-T cell therapy in clinical practice. The company has developed an autologous T-cell product LioCyx-M which is transferred with mRNA encoding HBV antigen-specific TCR, and it has been used clinically for the treatment of HBV-related liver cancer and recurrent HBV-related liver cancer post-liver transplant.
The company's revenue is generated by conducting ongoing clinical trials against hepatocellular carcinoma.
Current Investors
ABC Capital, Westlake Ventures, Smartech
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.liontcr.com/
Company Stage
Series B
Total Amount Raised
Subscriber access only
Lion TCR - timeline of key events
Lion TCR - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 21,163 | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | (100.0%) | - | - | - | - | - | - | - |
| EBITDA (USD) | (172,588) | (1,073,796) | (2,441,948) | (8,052,769) | (4,547,762) | (3,049,892) | (5,828,670) | - | - | - |
| Operating Income (USD) | (173,939) | (1,094,627) | (2,522,929) | (8,336,748) | (5,235,119) | (4,132,804) | (6,916,606) | - | - | - |
| Operating Margin | - | (5172.4%) | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | (5073.9%) | - | - | - | - | - | - | - | - |
| NET Income (USD) | (173,939) | (1,094,453) | (2,521,645) | (8,336,748) | (5,132,526) | (4,111,908) | (6,895,358) | - | - | - |
| % Net Margin | - | (5171.5%) | - | - | - | - | - | - | - | - |
Lion TCR - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.